Stocks and Investing
Stocks and Investing
Tue, November 2, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, November 1, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (ABBV) at Buy with Increased Target to $124 on, Nov 1st, 2021
Matthew Harrison of Morgan Stanley, Maintained "AbbVie Inc." (ABBV) at Buy with Increased Target from $116 to $124 on, Nov 1st, 2021.
Matthew has made no other calls on ABBV in the last 4 months.
There are 3 other peers that have a rating on ABBV. Out of the 3 peers that are also analyzing ABBV, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Geoff Meacham of "B of A Securities" Maintained at Hold with Increased Target to $119 on, Monday, August 2nd, 2021
These are the ratings of the 2 analyists that currently disagree with Matthew
- Steve Scala of "TD Cowen" Maintained at Buy with Increased Target to $130 on, Monday, August 23rd, 2021
- Robyn Karnauskas of "Truist Securities" Initiated at Strong Buy and Held Target at $118 on, Monday, July 26th, 2021
Contributing Sources